![]() |
|
|
Vol. 27, Issue 2, 246-249, February 1999
Gentest Corporation, Woburn, Massachusetts
| |
Abstract |
|---|
|
|
|---|
The effects of methanol, ethanol, dimethyl sulfoxide (DMSO), and
acetonitrile were studied in vitro on nine individual,
cDNAexpressed cytochrome P-450 activities (phenacetin
O-deethylase for CYP1A1 and CYP1A2, coumarin
7-hydroxylase for CYP2A6, testosterone 6
-hydroxylase for CYP3A4,
7-ethoxy-4-trifluoromethylcoumarin deethylase for CYP2B6, paclitaxel
6
-hydroxylase for CYP2C8, diclofenac 4'-hydroxylase for CYP2C9,
S-mephenytoin 4-hydroxylase for CYP2C19, and
(±)-bufuralol 1'-hydroxylase for CYP2D6) in commercially available
human lymphoblastoid microsomes. These data show that specific solvents
have enzyme-selective effects on P-450 activities. Methanol did not
substantially inhibit (
10%) any of the activities at 0.3%, but did
inhibit CYP1A1, CYP2B6, CYP2C9, and CYP2D6 by 12 to 26% at 1%. In
contrast, 0.1% ethanol inhibited CYP1A1, CYP2B6, and CYP2C19 by 20 to
30%. Ethanol at 1% did not inhibit CYP1A2, CYP3A4, CYP2C8, and
CYP2C9. DMSO inhibited CYP3A4, CYP2C19, and CYP2D6 by 15 to 25% at
0.1%. However, DMSO had little effect on CYP1A2, CYP2A6, and CYP2C8.
Acetonitrile, like methanol, did not inhibit any P-450 activity at
0.3% solvent except for CYP1A1 (26%) and CYP2B6 (13%). At 1%,
acetonitrile decreased activities of CYP1A1 and CYP2B6 by 40 to 60%,
and inhibited CYP2A6, CYP3A4, CYP2C19, and CYP2D6 activity by 10 to
20%. Acetonitrile also increased CYP2C9 activity by 10 to 15% above
control values at 1 to 3% solvent. Excluding solubility
considerations, methanol and acetonitrile appear to be the most
suitable solvents for the introduction of substances to cytochrome
P-450 incubations for in vitro metabolism studies.
| |
Introduction |
|---|
|
|
|---|
Cytochromes P-450 are the principal enzymes for the oxidation of drugs, environmental pollutants, and other xenobiotics. This enzyme system consists of many distinct forms of the enzyme. All mammalian forms are membrane bound and found in many tissues, but at highest levels in liver. A principal function of the cytochrome P-450 system is to convert lipophilic molecules into more water soluble forms which are more readily excreted from the body.
Because of the lipophilic nature of many cytochrome P-450 substrates, organic solvents are often required for solubilization of the substrate and addition to an in vitro incubation. However, the potential influence of these solvents on cytochrome P-450 activities has not been adequately studied. Therefore, there is the potential for artifacts should a chosen solvent type and concentration adversely affect the enzyme or enzymes of interest.
A few analyses of solvent inhibition have been reported. Chauret et al.
(1998)
and Hickman et al. (1998)
have reported the effects of several
organic solvents on enzyme-selective activities in human liver
microsomes. The former study examined multiple solvent concentrations
(0.2, 0.5, 1, and 5%); the latter examined a single concentration
(1%).
In the present study, we examine the inhibitory effects of four commonly used organic solvents, acetonitrile, dimethyl sulfoxide (DMSO),1 ethanol, and methanol, on substrate metabolism by the human extrahepatic cytochrome P-450 CYP1A1 and the hepatic forms, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.
| |
Materials and Methods |
|---|
|
|
|---|
Chemicals.
Glucose 6-phosphate, glucose 6-phosphate dehydrogenase,
NADP+, phenacetin, acetamidophenol, coumarin,
7-hydroxycoumarin, and diclofenac were purchased from Sigma (St. Louis,
MO). [14C]-(S)-mephenytoin was
obtained from Amersham Life Science (Arlington Heights, IL).
Testosterone and 6
-hydroxytestosterone were obtained from Steraloids
(Wilton, NH). Paclitaxel, 7-ethoxy-4-trifluoromethylcoumarin, and
7-hydroxy-4-trifluoromethylcoumarin were obtained from Molecular Probes
(Eugene, OR). 4'-Hydroxydiclofenac, (±)-bufuralol, and 6
-hydroxypaclitaxel were obtained from Gentest Corp. (Woburn, MA)
and (S)-mephenytoin and 1'-hydroxybufuralol were obtained from Ultrafine Chemicals, Ltd. (Manchester, UK). All other chemicals were analytical grade quality and all solvents were high-pressure liquid chromatography (HPLC) grade.
Microsomes. Microsomes were obtained from Gentest Corp. from metabolically competent human B lymphoblastoid cell lines that stably express human cytochromes P-450 1A1, 1A2, 2A6, 3A4, 2B6, 2C9, 2C19, and 2D6 (catalog nos. M111b, M103c, M104r, M107r, M110a, M118r, M119a, and M117r, respectively) or from baculovirus-insect cell-expressed CYP2C8 (Supersomes, catalog no. P212).
Cytochrome P-450 Assays.
Assays were performed in a final volume of 0.25 ml containing 1.3 mM
NADP+, 3.3 mM glucose 6-phosphate, 0.4 U/ml
glucose 6-phosphate dehydrogenase, 3.3 mM MgCl2,
and 50 mM (for CYP2A6 and CYP2C19) or 100 mM (for CYP1A1, CYP1A2,
CYP3A4, CYP2B6, CYP2C8, and CYP2D6) potassium phosphate buffer, pH 7.4. Assays for CYP2C9 were carried out in 100 mM Tris buffer, pH 7.5. Substrate, microsomal protein concentrations, and literature references
for the assays were as follows: CYP1A1 and CYP1A2, 100 µM phenacetin
and 400 µg/ml protein (Butler et al., 1989
); CYP2A6, 400 µM
coumarin and 200 µg/ml protein (Greenlee and Poland 1978
); CYP3A4,
120 µM testosterone and 200 µg/ml protein (Oldham and Clarke 1977
);
CYP2B6, 50 µM 7-ethoxy4-trifluoromethylcoumarin and 400 µg/ml
protein (DeLuca et al., 1988
); CYP2C8, 10 µM paclitaxel and 30 µg/ml protein (Rahman et al., 1994
); CYP2C9, 15 µM diclofenac and 17.2 µg/ml protein (Leeman et al., 1993
); CYP2C19, 100 µM [14C]-(S)-mephenytoin (specific
activity, 5.7 mCi/mmol) and 1 mg/ml protein (Wrighton et al., 1993
);
CYP2D6, 10 µM (±)-bufuralol and 100 µg/ml protein (Kronbach et
al., 1987
). Enzyme concentrations and incubation times were selected to
give less than 10% conversion into the measured metabolite to ensure
first order reaction rate kinetics. Incubations were carried out for 30 min at 37°C, except for 20 min with the CYP2C8 assay.
HPLC and Fluorometric Analysis. The HPLC system consisted of Waters model 510 pumps, a Waters model 717 plus Autosampler, and a Waters model 486 tunable absorbance detector or a model 996 photo diode array detector. This system was controlled by an IBM-compatible computer using Waters (Milford, MA) Milennium Version 2.15 software. Instead of absorbance detectors, a Packard Radiomatic Flo-One flow scintillation analyzer was used to detect peaks in the 2C19 assay and an Optical Technical Devices scanning spectrofluorometer (Elmsford, NY) was used in the 2D6 assay.
Aliquots of supernatant from all except the CYP2A6 and CYP2B6 assays were injected onto a Supelco 4.6 × 250-mm Nucleosil C18 5-µm HPLC column (Bellefonte, PA) and separated at 45°C with a flow rate of 1 ml/min. The HPLC column was protected by a Waters 3.9 × 20 mm 60A 4-µm Sentry guard column. Metabolite peaks were separated with 10% methanol (mobile phase A), 100% methanol (mobile phase B), or 30% acetonitrile-70% water-0.16 ml/liter 70% perchloric acid (mobile phase C) as follows:CYP1A1/CYP1A2 assay. This assay was as follows: initial conditions of 100% A changed to 85% A:15% B over 6 min, then changed to 100% B over 1 min and held for 5 min. The acetamidophenol product (Rt = 10 min) was detected by absorbance at 244 nm.
CYP2C8 assay.
This assay was as follows: initial conditions of 45% A:55% B (flow
rate = 0.5 ml/min) changed to 42.5% A:57.5% B (flow rate = 1.0 ml/min) over 5 min, then changed to 35% A:65%B over 20 min. The
6
-hydroxypaclitaxel product (Rt = 15 min) was
detected by absorbance at 230 nm.
CYP2C9 assay. This assay was as follows: initial conditions of 30% B:70% C changed to 100% B over 15 min and held for 1 min. The 4'-hydroxydiclofenac product (Rt = 12 min) was detected by absorbance at 280 nm.
CYP2C19 assay. This assay was as follows: initial conditions of 75% A:25% B changed to 100% B over 8 min and held for 3 min. The metabolite product (Rt = 8 min) was detected by flow liquid scintillation detection.
CYP2D6 assay. This assay was as follows: initial conditions of 100% C held for 7 min, then changed to 100% B over 1 min and held for 5 min. The 1'-hydroxybufuralol product (Rt = 5.5 min) was detected by fluorescence with excitation at 252 nm and emission at 302 nm.
CYP3A4 assay.
This assay was as follows: initial conditions of 47% A:53% B changed
to 42% A:58% B over 8 min, then changed to 100% B over 0.1 min and
held for 5.9 min. The 6
-hydroxytestosterone product (Rt = 8 min) was detected by absorbance at 254 nm.
Data Analysis. The results were obtained from at least four determinations (from duplicate incubations from at least two separate experiments) for each solvent concentration, using different lots of microsome preparations. Data are expressed as percentage of inhibition compared to control incubations containing no solvent.
| |
Results |
|---|
|
|
|---|
The effect of methanol, ethanol, DMSO, and acetonitrile on the catalytic activities of nine human cDNA-expressed cytochrome P-450s are shown in Table 1. Initially, experiments were performed at solvent concentrations of 0.3, 1, and 3%. In most instances where there was >20% inhibition at 0.3% solvent, additional experiments were done with overlapping solvent concentrations down to 0.1%. Acetonitrile was tested at higher concentrations (up to 10%) because preliminary experiments suggested that acetonitrile was a comparatively weak inhibitor of cytochrome P-450 activity.
|
Acetonitrile was observed to be only slightly inhibitory to CYP2B6 and not inhibitory to any of the other hepatic enzymes tested at a concentration of 0.3%. However, at 0.3% acetonitrile, 26% inhibition of the extrahepatic enzyme, CYP1A1, was observed. At 1%, a slight inhibition (<20%) of CYP1A2, CYP2A6, CYP2C19, CYP2D6, and CYP3A4 was observed. While at 3% only CYP2C9 was not inhibited; this lack of inhibition extended to 5% acetonitrile. At 10%, acetonitrile inhibited CYP2C9 activity by 62% and the other cytochrome P-450 activities by 92 to 100% (data not shown).
Methanol was not inhibitory to any enzyme at a concentration of 0.3%. At 1%, approximately 25% inhibition of CYP1A1 and CYP2D6 was observed with lower levels of inhibition noted for CYP2B6 and CYP2C9 (19% and 12%, respectively). CYP1A2, CYP2A6, and CYP2C8 were not inhibited by 3% methanol.
DMSO was slightly inhibitory (13%) to CYP2B6 and quite inhibitory (25-38%) to CYP2C19, CYP2D6, and CYP3A4 at a concentration of 0.3%. Further testing revealed that significant inhibition (17-23%) was still present at 0.1% DMSO. At 1 and 3% DMSO, only CYP1A2, CYP2A6, and CYP2C8 were not inhibited.
Ethanol was quite inhibitory (19-28%) to CYP1A1, CYP2B6, and CYP2C19 at a concentration of only 0.1%. At 0.3%, 24% inhibition of CYP2D6 was observed. At 1%, 18% inhibition of CYP2A6 was observed. While at 3%, only CYP2C9 was not inhibited but the inhibition of CYP2C8 was relatively small (16%).
| |
Discussion |
|---|
|
|
|---|
These results show that there is no consistent effect of any of the four common organic solvents examined on the activities of nine cDNA-expressed human cytochromes P-450 over a moderate solvent concentration range (0.1-3%). Any given solvent has a variable inhibitory effect on the different cytochromes examined and any given cytochrome P-450 activity is variably inhibited by the different solvents tested.
If one groups the effects by enzyme, CYP1A2, CYP2C8, and CYP2C9 appear to be the most resistant to inhibition by the tested organic solvents. CYP1A1, CYP2B6, CYP2C19, and CYP2D6 appear to be the most sensitive to inhibition by these solvents. The latter enzymes tolerate no solvents at concentrations at 3% and many solvents are substantially inhibitory at 1% or below. CYP2A6 and CYP3A4 have an intermediate response. CYP2A6 is inhibited by greater than 1% ethanol or acetonitrile, whereas CYP3A4 is inhibited by all solvents at 3% and by only DMSO at lower concentrations.
Clearly, purely aqueous incubation conditions are preferred for cytochrome P-450 incubations. If an organic solvent must be used, methanol appears to be the most suitable for this purpose. This conclusion is based on our observation that none of the cytochromes P-450 tested were inhibited more than 10% by 0.3% methanol. Likewise, acetonitrile demonstrates modest inhibitory effects. There was no substantial inhibition (<10%) of most cytochromes P-450 at 0.3% acetonitrile, except for CYP2B6 (13%) and the extrahepatic form, CYP1A1 (26%). Both ethanol and DMSO substantially inhibited (10-30%) some cytochromes as low as 0.1% solvent.
Two similar studies on the effects of organic solvents on a number of
cytochrome P-450 activities in human liver microsomes have been
recently reported (Chauret et al., 1998
; Hickman et al., 1998
). Chauret
et al. (1998)
examined multiple solvent concentrations. Hickman et al.
(1998)
examined only a single concentration (1%). Although there are
differences in enzyme source and some of the assay conditions, there
were many similarities in the results of the three studies. For
example, CYP1A2 activity was not affected substantially by methanol at
concentrations
1%. Coumarin 7-hydroxylase (CYP2A6) activity was
affected by methanol or DMSO at
5%. A similar observation at 1%
solvent has also been reported (Draper et al., 1997
). In the
testosterone 6
-hydroxylase (CYP3A4) assay, there was little effect
with methanol and acetonitrile at levels
0.5%, and DMSO was strongly
inhibitory at low (0.2%) concentrations (this report and Chauret et
al., 1998
). For CYP2C19 activity, strong inhibition at low
concentrations of DMSO was observed, as well as little inhibition by
methanol and acetonitrile at concentrations
1%. Ethanol as a solvent
and the other solvent effects on CYP1A1, CYP2B6, or CYP2C8 activities
were not tested by Chauret et al. (1998)
or Hickman et al. (1998)
.
There are examples of differences between our data and that previously
reported (Chauret et al., 1998
; Hickman et al., 1998
). For example,
Hickman et al. (1998)
observed DMSO to inhibit caffeine 3-demethylase
activity, whereas we and Chauret et al. (1998)
observed DMSO to be less
inhibitory to phenacetin O-deethylase activity. Chauret et
al. (1998)
and Hickman et al. (1998)
observed inhibition of tolbutamide
hydroxylation (CYP2C8/9) by methanol and DMSO. In contrast, we observed
paclitaxel 6
-hydroxylase (CYP2C8) activity and diclofenac
4'-hydroxylase (CYP2C9) activity were only slightly inhibited (<15%)
by up to 3% methanol or by 1% DMSO. Another point of difference was
that Chauret et al. (1998)
and Hickman et al. (1998)
recorded little
inhibition of dextromethorphan O-demethylase activity at
methanol and DMSO concentrations
1%. By contrast, our findings
showed significant inhibition of CYP2D6 catalyzed bufuralol
1'-hydroxylase by 0.3% DMSO (38%) and 1% methanol (26%). Hickman et
al. (1998)
did not observe dextromethorphan N-demethylase activity (CYP3A4) to be inhibited by DMSO, whereas we and Chauret et
al. (1998)
observed testosterone 6
-hydroxylase activity to be
substantially inhibited.
The results from our study with single recombinant human cytochromes
P-450 generally agree with the results from previously published
studies with human liver microsomes (Chauret et al., 1998
; Hickman et
al., 1998
) only when the enzyme/substrate pairs are the same (i.e.,
1A2/phenacetin, 2A6/coumarin, 2C19/(S)-mephenytoin, and
3A4/testosterone). All major points of difference involve a change in
substrate, suggesting that the inhibitory effects of solvents are
substrate-dependent for a given cytochrome P-450. Further
experimentation is required to define the extent of this substrate selectivity.
We wish to emphasize several practical implications from results
reported here and those previously reported (Chauret et al., 1998
;
Hickman et al., 1998
).
If one is evaluating the relative rates of metabolism of a substrate to different products, one should select a solvent type and concentration that are not inhibitory to the participating enzymes. It may be desirable to examine two solvent concentrations to verify that the selected conditions do not affect the results.
If one is evaluating potentially selective probe substrates or
inhibitors for the CYP1A subfamily, solvent choice may be problematic. Our results and those of Chauret et al. (1998)
suggest the use of
methanol or DMSO (0.3% or less) is preferred to avoid inhibiting CYP1A1. Hickman et al. (1998)
observed a 1% concentration of these solvents to be quite inhibitory to CYP1A2-catalyzed caffeine
N-demethylase activity.
DMSO is the solvent of choice for solubilization of chemical libraries for high throughput screening applications for pharmacological activity. Three major drug-metabolizing enzymes (CYP2C19, CYP2D6, and CYP3A4) are profoundly inhibited by this solvent in our study. Therefore, if cytochrome P-450-mediated metabolic data are to be obtained, the chemical library should be prepared in an alternative solvent.
It seems possible that the selectivity of inhibition of organic solvents could be exploited to improve the selectivity of the enzyme-selective probe assays. For example, if a specific biotransformation is catalyzed by two enzymes, and the minor contributing enzyme, but not the major contributing enzyme, is inhibited by a specific concentration of solvent, then the addition of a selected solvent at the correct concentration can improve the selectivity of the biotransformation for the major contributing enzyme.
Commercially available radiolabeled (S)-mephenytoin is
supplied as an ethanol solution. Since this substrate is commonly used to assay not only CYP2C19, but also CYP2B6 (Heyn et al., 1996
), it is
critical that ethanol be removed before use.
Finally, it appears noteworthy that ethanol is a significant inhibitor of CYP1A1, CYP2B6, and CYP2C19 at the lowest solvent concentration tested (0.1%). Similar blood human alcohol concentrations are not uncommon and may have implications to in vivo xenobiotic metabolism and drug pharmacokinetics.
| |
Footnotes |
|---|
Received May 29, 1998; accepted November 4, 1998.
Send reprint requests to: Dr. William F. Busby, Jr., Gentest Corporation, 6 Henshaw Street, Woburn, MA 01801. E-mail: bbusby{at}gentest.com
| |
Abbreviations |
|---|
Abbreviations used are: DMSO, dimethyl sulfoxide; HPLC, high-pressure liquid chromatography.
| |
References |
|---|
|
|
|---|
)-carvedilol.
Drug Metab Dispos
25:
970-977
-hydroxytaxol by human cytochrome P450 2C8.
Cancer Res
54:
5543-5546This article has been cited by other articles:
![]() |
A. P. Li Evaluation of Luciferin-Isopropyl Acetal as a CYP3A4 Substrate for Human Hepatocytes: Effects of Organic Solvents, Cytochrome P450 (P450) Inhibitors, and P450 Inducers Drug Metab. Dispos., August 1, 2009; 37(8): 1598 - 1603. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Siller, P. Anzenbacher, E. Anzenbacherova, K. Dolezal, I. Popa, and M. Strnad Interactions of Olomoucine II with Human Liver Microsomal Cytochromes P450 Drug Metab. Dispos., June 1, 2009; 37(6): 1198 - 1202. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Vuppugalla, S.-Y. Chang, H. Zhang, P. H. Marathe, and D. A. Rodrigues Effect of Commonly Used Organic Solvents on the Kinetics of Cytochrome P450 2B6- and 2C8-Dependent Activity in Human Liver Microsomes Drug Metab. Dispos., November 1, 2007; 35(11): 1990 - 1995. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Di Marco, A. Cellucci, A. Chaudhary, M. Fonsi, and R. Laufer High-Throughput Radiometric CYP2C19 Inhibition Assay Using Tritiated (S)-Mephenytoin Drug Metab. Dispos., October 1, 2007; 35(10): 1737 - 1743. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Kammerer, H. Scheible, W. Albrecht, C. H. Gleiter, and S. Laufer Pharmacokinetics of ML3403 ({4-[5-(4-Fluorophenyl)-2-methylsulfanyl-3H-imidazol-4-yl]-pyridin-2-yl}-(1-phenylethyl)-amine), a 4-Pyridinylimidazole-Type p38 Mitogen-Activated Protein Kinase Inhibitor Drug Metab. Dispos., June 1, 2007; 35(6): 875 - 883. [Abstract] [Full Text] [PDF] |
||||
![]() |
M Iwase, N Kurata, R Ehana, Y Nishimura, T Masamoto, and H Yasuhara Evaluation of the effects of hydrophilic organic solvents on CYP3A-mediated drug-drug interaction in vitro Human and Experimental Toxicology, December 1, 2006; 25(12): 715 - 721. [Abstract] [PDF] |
||||
![]() |
A. E. Cribb, M. J. Knight, D. Dryer, J. Guernsey, K. Hender, M. Tesch, and T. M. Saleh Role of polymorphic human cytochrome p450 enzymes in estrone oxidation. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 551 - 558. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hallifax, H. C. Rawden, N. Hakooz, and J. B. Houston PREDICTION OF METABOLIC CLEARANCE USING CRYOPRESERVED HUMAN HEPATOCYTES: KINETIC CHARACTERISTICS FOR FIVE BENZODIAZEPINES Drug Metab. Dispos., December 1, 2005; 33(12): 1852 - 1858. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. D. Marks, D. V. Thompson, T. A. Goossens, and O. V. Trubetskoy High-Throughput Screening Assays for the Assessment of CYP2C9*1, CYP2C9*2, and CYP2C9*3 Metabolism Using Fluorogenic Vivid(R) Substrates J Biomol Screen, August 1, 2004; 9(5): 439 - 449. [Abstract] [PDF] |
||||
![]() |
D. M. Stresser, M. I. Broudy, T. Ho, C. E. Cargill, A. P. Blanchard, R. Sharma, A. A. Dandeneau, J. J. Goodwin, S. D. Turner, J. C. L. Erve, et al. HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE Drug Metab. Dispos., January 1, 2004; 32(1): 105 - 112. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Ma, M. Shou, and M. L. Schrag SOLVENT EFFECT ON cDNA-EXPRESSED HUMAN SULFOTRANSFERASE (SULT) ACTIVITIES IN VITRO Drug Metab. Dispos., November 1, 2003; 31(11): 1300 - 1305. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Di, E. H. Kerns, Y. Hong, T. A. Kleintop, O. J. Mc Connell, and D. M. Huryn Optimization of a Higher Throughput Microsomal Stability Screening Assay for Profiling Drug Discovery Candidates J Biomol Screen, August 1, 2003; 8(4): 453 - 462. [Abstract] [PDF] |
||||
![]() |
R. Yuan, S. Madani, X.-X. Wei, K. Reynolds, and S.-M. Huang Evaluation of Cytochrome P450 Probe Substrates Commonly Used by the Pharmaceutical Industry to Study in Vitro Drug Interactions Drug Metab. Dispos., December 1, 2002; 30(12): 1311 - 1319. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Hanioka, S. Ozawa, H. Jinno, T. Tanaka-Kagawa, T. Nishimura, M. Ando, and J.-i. Sawada Interaction of Irinotecan (CPT-11) and Its Active Metabolite 7-Ethyl-10-Hydroxycamptothecin (SN-38) with Human Cytochrome P450 Enzymes Drug Metab. Dispos., April 1, 2002; 30(4): 391 - 396. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Fowler, J. M. Taylor, T. Friedberg, C. R. Wolf, and R. J. Riley CYP3A4 Active Site Volume Modification by Mutagenesis of Leucine 211 Drug Metab. Dispos., April 1, 2002; 30(4): 452 - 456. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chen, S. Ricks, D. R. Doody, E.D. Fitzgibbons, P. L. Porter, and S. M. Schwartz N-Acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk Carcinogenesis, December 1, 2001; 22(12): 1993 - 1999. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Chauret, B. Dobbs, R. L. Lackman, K. Bateman, D. A. Nicoll-Griffith, D. M. Stresser, J. M. Ackermann, S. D. Turner, V. P. Miller, and C. L. Crespi The Use of 3-[2-(N,N-Diethyl-N-methylammonium)ethyl]-7-methoxy-4-methylcoumarin (AMMC) as a Specific CYP2D6 Probe in Human Liver Microsomes Drug Metab. Dispos., September 1, 2001; 29(9): 1196 - 1200. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Subrahmanyam, A. B. Renwick, D. G. Walters, P. J. Young, R. J. Price, A. P. Tonelli, and B. G. Lake Identification of Cytochrome P-450 Isoforms Responsible for cis-Tramadol Metabolism in Human Liver Microsomes Drug Metab. Dispos., August 1, 2001; 29(8): 1146 - 1155. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. K. Turan, V. M. Mishin, and P. E. Thomas Clotrimazole is a Selective and Potent Inhibitor of Rat Cytochrome P450 3A Subfamily-Related Testosterone Metabolism Drug Metab. Dispos., June 1, 2001; 29(6): 837 - 842. [Abstract] [Full Text] |
||||
![]() |
L. M. Hesse, K. Venkatakrishnan, L. L. von Moltke, R. I. Shader, and D. J. Greenblatt CYP3A4 Is the Major CYP Isoform Mediating the in Vitro Hydroxylation and Demethylation of Flunitrazepam Drug Metab. Dispos., February 1, 2001; 29(2): 133 - 140. [Abstract] [Full Text] |
||||
![]() |
J. Easterbrook, C. Lu, Y. Sakai, and A. P. Li Effects of Organic Solvents on the Activities of Cytochrome P450 Isoforms, UDP-Dependent Glucuronyl Transferase, and Phenol Sulfotransferase in Human Hepatocytes Drug Metab. Dispos., February 1, 2001; 29(2): 141 - 144. [Abstract] [Full Text] |
||||
![]() |
H. Yin, P. Tran, G. E. Greenberg, and V. Fischer Methanol Solvent May Cause Increased Apparent Metabolic Instability in in Vitro Assays Drug Metab. Dispos., February 1, 2001; 29(2): 185 - 193. [Abstract] [Full Text] |
||||
![]() |
C. Tang, M. Shou, and A. D. Rodrigues Substrate-Dependent Effect of Acetonitrile on Human Liver Microsomal Cytochrome P450 2C9 (CYP2C9) Activity Drug Metab. Dispos., May 1, 2000; 28(5): 567 - 572. [Abstract] [Full Text] |
||||
![]() |
J. Palamanda, W.-W. Feng, C.-C. Lin, and A. A. Nomeir Stimulation of Tolbutamide Hydroxylation by Acetone and Acetonitrile in Human Liver Microsomes and in a Cytochrome P-450 2C9-Reconstituted System Drug Metab. Dispos., January 1, 2000; 28(1): 38 - 43. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||